Kither Biotech
Emilio Hirsch has a diverse work experience. Emilio started their career in 2005 as a Professore Ordinario at Universita' degli Studi di Torino, where they worked until an unspecified date. In 2011, they founded Kither Biotech and continues to be involved with the company. In 2015, they became a Member of the Advisory Board at Kaleyra. Their most recent position is as a docente responsabile per il campo biomedico - membro della giunta amministrativa at Scuole di Dottorato - Università degli Studi di Torino, which they started in December 2018.
Emilio Hirsch began their education at Colonna e Finzi; Artom; Gobetti school in 1971 and completed their Bachelor's degree, although the specific field of study is not mentioned. Later, from 1984 to 1988, they attended Università degli Studi di Torino, where they earned a Doctorate degree in Molecular Biology.
This person is not in any teams
Kither Biotech
Kither Biotech is a pharmaceutical product company that focuses its R&D activities on the development of new drugs. The R&D activities of the company mainly involve the development of new drugs to treat chronic inflammatory diseases.In recent years Kither has focused its first line of activities on the development of a small peptide(KIT2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure. The KIT2014 peptide was assigned the Orphan Drug designation from the European Medicines Agency. The KIT2014 compound is currently undergoing the pre-clinical phase of clinical development.Kither’s product portfolio also includes a molecule (CL27), also developed internally, that is being developed for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma. The company is about to start the pre-clinical phase of development of the CL27 molecule.